Briacell Therapeutics Revenue Growth Rates (BCTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Briacell Therapeutics Corp   (NASDAQ: BCTX)
 

BCTX's Revenue Growth by Quarter and Year

Briacell Therapeutics 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BCTX/growth
https://api.csimarket.com/api/v1/companies/BCTX/fundamentals
https://api.csimarket.com/api/v1/companies/BCTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BCTX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter July 0.00
3rd Quarter April 0.00
2nd Quarter January 0.00
1st Quarter October 0.00
FY 0.00





BCTX Revenue fourth quarter 2025 Y/Y Growth Comment
Briacell Therapeutics Corp in the fourth quarter 2025 recorded of $ 0.00 millions.

According to the results reported in the fourth quarter 2025, Briacell Therapeutics Corp achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Briacell Therapeutics Corp ' s Revenue no change of 0% ranks overall at the positon no. in the fourth quarter 2025.


BCTX Revenue ( Y/Y Growth %) 2025
 FY 2024 FY 2023 FY 2022
4th Quarter July -
3rd Quarter April -
2nd Quarter January -
1st Quarter October -
FY   -

Financial Statements
Briacell Therapeutics 's fourth quarter 2025 Revenue $ 0.00 millions BCTX's Income Statement
Briacell Therapeutics 's fourth quarter 2024 Revenue $ 0.00 millions Quarterly BCTX's Income Statement


BCTX Revenue (Quarter on Quarter Growth %)

 2025
 FY 2024 FY 2023 FY 2022
4th Quarter July -
3rd Quarter April -
2nd Quarter January -
1st Quarter October -
FY (Year on Year)   -


Back to BCTX Growth rate Comparisons >> Back to BCTX Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Briacell Therapeutics 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BCTX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BCTX's IV. Quarter Q/Q Revenue Comment


Briacell Therapeutics 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jul 31 2026)		 12 Months Ending (Apr 30 2026) 12 Months Ending (Jan 31 2026) 12 Months Ending (Oct 31 2025) 12 Months Ending (Jul 31 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Jul 31 2026 period, Briacell Therapeutics 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Briacell Therapeutics Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jul 31 2026 period, Briacell Therapeutics 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Briacell Therapeutics Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BCTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Jul 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jul 31 2026
Lakeland Industries Inc -4.49%$ -4.490 millions
Kewaunee Scientific Corporation-6.50%$ -6.499 millions
Nutriband Inc -29.71%$ -29.711 millions


About Briacell Therapeutics Revenue Growth Rates (BCTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Briacell Therapeutics Corp (CIK 1610820).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-049041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Briacell Therapeutics Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.